The target is to reduce its workforce to less than 5,000 from a level of 5,800 at the end of 2024, said chief executive ...

Hemlibra (emicizumab), the only treatment currently available for haemophilia A via the NHS that doesn't require an ...

The recent move to introduce an “Amazon-style” prescription tracking in the NHS App is a crucial first step. People want ...

From trade associations to medtech innovators and biotech start-ups, here’s a comprehensive look at the latest boardroom ...

"For decades, bureaucrats and entrenched interests buried health data and blocked patients from taking control of their ...

At ASCO 2025, Actuate gave an oral presentation on positive Phase 2 combination data for elraglusib, highlighting its ...

When Tidmarsh was appointed to CDER, the FDA emphasised his academic and clinical credentials – including his role as ...

The foundational model could also assist Google and partner Samsung in an ongoing rivalry with Apple, currently the leader in ...

President Donald Trump has given leading pharma manufacturers a 60-day deadline to come up with a most favoured nation (MFN) ...

The results of the SURPASS-CVOT trial showed that dual GLP-1/GIP agonist Mounjaro (tirzepatide) was as effective as Lilly's ...

The problem of medical misinformation on the Internet was brewing before the COVID-19 pandemic, but the combustible discourse ...

MSD has said it will cut $3 billion off its annual costs by the end of 2027 as it prepares for the end of patent protection ...